Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1

European Heart Journal

Volumn 20, Issue 24, 1999, Pages 1799-1807

  Tsutamoto, T ^a   Wada, A ^a   Maeda, K ^a   Hisanaga, T ^a   Mabuchi, N ^a   Hayashi, M ^a   Ohnishi, M ^a   Sawaki, M ^a   Fujii, M ^a   Horie, H ^a   Sugimoto, Y ^a   Kinoshita, M ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Angiotensin II; Asymptomatic left ventricular dysfunction; Brain natriuretic peptide; Morbidity; Mortality

Indexed keywords

ANGIOTENSIN; BIOCHEMICAL MARKER; BRAIN NATRIURETIC PEPTIDE; NORADRENALIN;

ADULT; AGED; ANGIOTENSIN BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE FAILURE; HEMODYNAMICS; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN II; BIOLOGICAL MARKERS; ENDOTHELIN-1; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOIMMUNOASSAY; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; SURVIVAL RATE; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR PRESSURE;

EID: 0032785114     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1999.1746     Document Type: Article

References (28)

1. Francis GS, Goldsmith SR, Levine TB, Olivari MT, Cohn JN. The neurohumoral axis in congestive heart failure. Ann Intern Med 1984; 101: 370-7.
2. Cohn JN, Levine TB, Olivari MT et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311: 819-23.
3. Packer M. Neurohumoral interactions and adaptations in congestive heart failure. Circulation 1988; 77: 721-9.
4. Remes J, Tikkanen I, Fyhrquist F, Ryoarala K. Neuroendocrine activity in untreated heart failure. Br Heart J 1991; 65: 249-55.
5. Tsutamoto T, Wada A, Maeda Y, Adachi T, Kinoshita M. Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. J Am Coll Cardiol 1994; 23: 1427-33.
6. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L, for the CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990; 82: 1730-6.
7. Rouleau JL, Packer M, Moye L et al. Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril. J Am Coll Cardiol 1994; 24: 583-91.
8. Tsutamoto T, Hisanaga T, Fukai D et al. Prognostic value of plasma intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic congestive heart failure. Am J Cardiol 1995; 76: 803-8.
9. Gottlieb SS, Kukin MC, Ahern D, Packer M. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol 1989; 13: 1534-9.
10. Hall C, Rouleau JL, Moye L et al. N-terminal proatrial natriuretic factor: an independent predictor of long-term prognosis after myocardial infarction. Circulation 1994; 89: 1934-42.
11. Benedict CR, Francis GS, Shelton B et al., for the SOLVD Investigators. Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction. Am J Cardiol 1995; 75: 1151-7.
12. Yoshimura M, Yasue H, Okumura K et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 1993; 87: 464-9.
13. Morita E, Yasue H, Yoshimura M et al. Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 1993; 88: 82-91.
14. Motwani JG, McAlpine H, Kennedy N, Struthers AD. Plasma brain natriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction. Lancet 1993; 341: 1109-13.
15. Yasue H, Yoshimura M, Sumida H et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994; 90: 195-203.
16. Bates ER, Shenker Y, Grekin RJ. The relationship between plasma levels of immunoreactive atrial natriuretic hormone and hemodynamic function in man. Circulation 1986; 73: 1155-61.
17. Raine AEG, Phil D, Erne P et al. Atrial natriuretic peptide and atrial pressure in patients with congestive heart failure. N Engl J Med 1986; 315: 533-7.
18. Tsutamoto T, Bito K, Kinoshita M. Plasma atrial natriuretic polypeptide as an index of left ventricular end-diastolic pressure in patients with chronic left-sided heart failure. Am Heart J 1989; 117: 599-606.
19. Omland T, Aakvaag A, Bonarjee VVS et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction: comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 1996; 93: 1963-9.
20. Tsutamoto T, Wada A, Maeda K et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997; 96: 509-16.
21. Benedict CR, Shelton B, Johnstone DE et al., for the SOLVD Investigators. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. Circulation 1996; 94: 690-7.
22. White HD, Norris RM, Brown MA, Brandt PWT, Whitlock RML, Wild CJ. Left ventricular end-systolic volume as the major determinant of survival after recovery from the myocardial infarction. Circulation 1987; 76: 44-51.
23. Cowie MR, Struthers AD, Wood DA et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997; 350: 1349-53.
24. McDonagh TA, Robb SD, Murdoch DR et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998; 351: 9-13.
25. The Captopril-Digoxin Multicenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA 1988; 259: 539-44.
26. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L, for the CONSENSUS Trial Study Group. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 1990; 82: 1730-6.
27. Biollaz J, Brunner HR, Gavras I, Waeber B, Gavras H. Antihypertensive therapy with MK421: angiotensin II-renin relations to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol 1982; 4: 966-72.
28. Omland T, Bonarjee VVS, Lie RT, Caidahl K. Neurohumoral measurements as indicators of long-term prognosis after myocardial infarction. Am J Cardiol 1995; 76: 230-5.